Current Options for Highly Treatment-Experienced People With HIV BY MILENA MURRAY, PHARMD, MSC, BCIDP, AAHIVP, FCCP
T
he treatment of HIV has dramatically advanced over the past 40 years. Clear data show a decreased occurrence of AIDS and an increased life expectancy.1,2 However, a small percentage of the overall population with HIV cannot achieve treatment goals. People with HIV who are highly treatment-experienced (HTE) may have limited antiretroviral therapy (ART) options due to resistance or tolerability issues. This population may have problems with virologic suppression, immune function, toxicities, and drug–drug interactions. These challenges may lead to an overall decrease in health-related quality of life (HRQOL).3 HTE people with HIV need novel ART options and classes with improved tolerability and no crossresistance to current ART classes. Transmitted and acquired resistance must be considered in the HIV treatment discussion. In a World Health Organization survey report, there was more than 10% resistance to nevirapine or efavirenz in people with HIV initiating therapy.4 This global prevalence of resistance to the nonnucleoside reverse transcriptase inhibitors emphasizes the need to use ART with long-term efficacy and durability.4 There is also a need to retain these patients in care and encourage adherence. Global access to HIV RNA testing is needed to ensure that ART is effective and to rapidly identify cases of virologic failure.4 Overall resistance rates to 4 ART classes are thought to be low; however, reported prevalence rates to 3 and 4 ART classes are estimated to be 5% to 10% in Europe and less than 3% in North America.1,5 In the United States, approximately 12,000 people with multidrug-resistant HIV need novel agents.2,6 When HIV RNA
undetectability cannot be achieved, a secondary goal is to reduce the HIV RNA levels as much as possible and maintain immunologic function. 7 Entry inhibitors are second-line agents that prevent HIV-1 cellular entry by binding a cellular target.1 Enfuvirtide (Fuzeon, Genentech) and maraviroc were the first agents in this class; however, there are several disadvantages to these agents, including the route of administration, pill burden, and lower virologic efficacy compared with other ART options.1 The newest agents in the entry inhibitor class are fostemsavir (Rukobia, ViiV) and ibalizumab-uiyk (Trogarzo, Theratechnologies). Fostemsavir is an HIV-1 attachment inhibitor that binds the gp120 envelope glycoprotein and prevents viral connection to CD4 T cells. The drug was approved in July 2020 and has no apparent cross-resistance to other ART classes.3 Within the same drug class, there is no cross-resistance with ibalizumab-uiyk or maraviroc.8,9 Fostemsavir
is dosed as 600-mg tablets orally twice daily without regard to food.1 One concern with twice-daily administration is that nonadherence may have led to virologic failure, and adhering to a twicedaily regimen may be an issue for some people with HIV.6 Common adverse reactions with fostemsavir include nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, and sleep disturbances.6 Fostemsavir was studied in people with HIV who failed to respond to their current ART, and this agent also may be used for tolerability issues.10 This drug, combined with optimized background therapy, showed robust and sustained virologic and immunologic responses.11 Patient-reported outcomes from the BRIGHTE trial showed improved HRQOL outcomes.3 These improved outcomes are thought to increase overall adherence to ART, leading to better health outcomes. A case report of the use of fostemsavir to overcome a drug–drug interaction issue also has been published.12
INFECTIOUS DISEASE SPECIAL EDITION • SUMMER 2022
69
